Genmab down after trial data for AbbVie-partnered Epkinly in B-cell lymphoma
Genmab (GMAB) on Friday announced that its bispecific antibody epcoritamab, marketed as Epkinly in partnership with AbbVie...
Tag: ABBV
Ipsen rises on FDA breakthrough therapy status for blood cancer therapy
Ipsen (IPSEY) (IPSEF) shares traded higher in Paris on Wednesday after the U.S. FDA issued Breakthrough Therapy Designation...
Ipsen rises on FDA breakthrough therapy status for blood cancer therapy
Ipsen (IPSEY) (IPSEF) shares traded higher in Paris on Wednesday after the U.S. FDA issued Breakthrough Therapy Designation...
AbbVie secures tariff relief in drug pricing deal, pledges $100B investment
AbbVie (ABBV) has reached a three-year deal with the Trump administration to reduce drug prices and invest $100 billion in...
AbbVie in up to $5.6B deal with RemeGen for bispecific antibody for solid tumors
AbbVie (ABBV) has inked a licensing deal with China-based RemeGen for the latter's RC148, a PD-1/VEGF-targeted bispecific...
AbbVie to buy Arizona manufacturing facility from West Pharmaceutical
AbbVie (ABBV) has agreed to acquire a device manufacturing facility in Tempe, Arizona and associated intellectual property...
AbbVie sees negative Q4 EPS impact from IPR&D expenses
AbbVie (ABBV) said it will incur acquired IPR&D and milestones expenses of $1.3B in its Q4 financial results, leading...
Merck rises as Wolfe upgrades to Outperform; AbbVie downgraded
Merck (MRK) shares gained on Thursday as Wolfe Research upgraded the pharma giant to Outperform from Peer Perform, while...
AbbVie flags $1.3B IPR&D charge, warns of Q4 earnings pressure
AbbVie (ABBV) on Wednesday said it expects a significant impact on fourth-quarter earnings due to charges related to...
AbbVie says not in talks to buy Revolution Medicines – report
AbbVie (ABBV) said it's not in talks to buy Revolution Medicines (RVMD). Shares of Revolution Medicines sunk 14% in...